The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Hepatotoxicity of Chemotherapy
Abstract
After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients
Pratt, D. S., & Kaplan, M. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421707 · Cited by 1,203
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
A clinical review of bleomycin—a new antineoplastic agent
Blum, R. H., Carter, S. K., & Agre, K. (1973) · Cancer · doi:10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n · Cited by 864
KEMENY, N., DALY, J., REICHMAN, B., GELLER, N., BOTET, J., & ODERMAN, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-459 · Cited by 649
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
ELLISON, R. R., HOLLAND, J. F., WEIL, M., JACQUILLAT, C., BOIRON, M., BERNARD, J., SAWITSKY, A., ROSNER, F., GUSSOFF, B., SILVER, R. T., et al. (1968) · Blood · doi:10.1182/blood.v32.4.507.507 · Cited by 549
Cancer chemotherapy and biotherapy: Principles and practice
Ellis, L. E. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)00005-4 · Cited by 418
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chabner, B. A., & Longo, D. L. (1996) · Cited by 409
Grochow, L. B., Jones, R. J., Brundrett, R. B., Braine, H. G., Chen, T.-L., Saral, R., Santos, G. W., & Colvin, O. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694339 · Cited by 404
Benjamin, R. S., Wiernik, P. H., & Bachur, N. R. (1974) · Cancer · doi:10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m · Cited by 390
Martin, J. K. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410200086013 · Cited by 375
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
Maria, V. A., & Victorino, R. M. (1997) · Hepatology · doi:10.1002/hep.510260319 · Cited by 351
Pancreatic Islet Cell Carcinoma: II. Results of Therapy with Streptozotocin in 52 Patients
BRODER, L. E., & CARTER, S. K. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-108 · Cited by 349
Interferons in the treatment of human cancer.
Kirkwood, J. M., & Ernstoff, M. S. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.4.336 · Cited by 332
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
SHENKENBERG, T. D., & VON HOFF, D. D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-67 · Cited by 305
Lee, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331706 · Cited by 305
Toxicity of E. coli L-asparaginase in man
Oettgen, H. F., Stephenson, P. A., Schwartz, M. K., Leeper, R. D., Tallal, L., Tan, C. C., Clarkson, B. D., Golbey, R. B., Krakoff, I. H., Karnofsky, D. A., et al. (1970) · Cancer · doi:10.1002/1097-0142(197002)25:2<253::aid-cncr2820250204>3.0.co;2-u · Cited by 290
Shulman, H. M., McDonald, G. B., Matthews, D., Doney, K. C., Kopecky, K. J., Gauvreau, J. M., & Thomas, E. D. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90911-7 · Cited by 286
Taxanes: A New Class of Antitumor Agents
Huizing, M. T., Misser, V. H. S., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., & Beijnen, J. H. (1995) · Cancer Investigation · doi:10.3109/07357909509031919 · Cited by 285
WANLESS, I. R., GODWIN, T. A., ALLEN, F., & FEDER, A. (1980) · Medicine · doi:10.1097/00005792-198009000-00004 · Cited by 272
L-Asparaginase: Therapeutic and Toxic Effects in Patients with Neoplastic Disease
Haskell, C. M., Canellos, G. P., Leventhal, B. G., Carbone, P. P., Block, J. B., Serpick, A. A., & Selawry, O. S. (1969) · New England Journal of Medicine · doi:10.1056/nejm196911062811902 · Cited by 263
Topoisomerase I inhibitors: topotecan and irenotecan
Creemers, G. J., Lund, B., & Verweij, J. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90011-6 · Cited by 252
Wanless, I. R., Ta, G., Allen, F., et al. (1980) · PubMed · Cited by 235
Aapro, M. S., Martin, C., & Hatty, S. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199803000-00001 · Cited by 228
Chitturi, S., & Farrell, G. C. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0034-7 · Cited by 220
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
Vt, D. V., Pp, C., Owens, A. H., Gold, G. L., Mj, K., & Edmonson, J. H. (1965) · PubMed · Cited by 218
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)
Schein, P. S., O'Connell, M. J., Blom, J., Hubbard, S., Magrath, I. T., Bergevin, P., Wiernik, P. H., Ziegler, J. L., & Devita, V. T. (1974) · Cancer · doi:10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t · Cited by 190
Meredith, M. J., & Reed, D. J. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90451-3 · Cited by 177
Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine.
Hohn, D., Melnick, J., Stagg, R., Altman, D., Friedman, M., Ignoffo, R., Ferrell, L., & Lewis, B. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.1.98 · Cited by 176
Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C
García-Buey, L., García-Monzón, C., Rodriguez, S., Borque, M. J., García-Sánchez, A., Iglesias, R., DeCastro, M., Mateos, F. G., Vicario, J., Balas, A., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90139-6 · Cited by 172
Chaparral Ingestion: The Broadening Spectrum of Liver Injury Caused by Herbal Medications
Gordon, D. (1995) · JAMA · doi:10.1001/jama.273.6.489 · Cited by 160
Metabolic and toxic effects of mithramycin during tumor therapy
Kennedy, B. J. (1970) · The American Journal of Medicine · doi:10.1016/s0002-9343(70)80044-4 · Cited by 160
Berkowitz, R. S., GOLDSTEIN, D. P., & Bernstein, M. R. (1986) · Gynecologic Oncology · doi:10.1016/0090-8258(86)90123-x · Cited by 157
Lazarus, H. M., Herzig, R. H., Graham‐Pole, J., Wolff, S. N., Phillips, G. L., Strandjord, S. E., Hurd, D. D., Forman, W. B., Gordon, E. M., & Coccia, P. F. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.6.359 · Cited by 148
Veno‐occlusive disease of the liver after hemopoietic cell transplantation
Carreras, E. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.9r200.x · Cited by 140
Hepatic veno-occlusive disease
Rollins, B. J. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90266-4 · Cited by 139
Hepatotoxicity of Mercaptopurine
Einhorn, M., & Davidsohn, I. (1964) · JAMA · doi:10.1001/jama.1964.03060350028007 · Cited by 134
Veno-Occlusive Disease of the Liver After Chemotherapy of Acute Leukemia
Griner, P. F., ELBADAWI, A., & PACKMAN, C. H. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-5-578 · Cited by 130
Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.
Hill, J. M., Loeb, E., MacLellan, A., Hill, N. O., Khan, A., & King, J. J. (1975) · PubMed · Cited by 125
THE TOXIC EFFECTS OF 6‐MERCAPTOPURINE AND RELATED COMPOUNDS
Philips, F. S., Sternberg, S. S., Hamilton, L. D., et al. (1954) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1954.tb40019.x · Cited by 123
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., & Laurie, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.12.2386 · Cited by 123
Li, T. C., Versland, M. R., & Wu, G. Y. (1998) · Humana Press eBooks · doi:10.1007/978-1-4612-1808-1_13 · Cited by 119
Principles of Antineoplastic Drug Development and Pharmacology
Schilsky, R. L., Milano, G. A., & Ratain, M. J. (1996) · Cited by 118
Drug-induced granulomatous hepatitis.
McMaster, K., & Hennigar, G. R. (1981) · PubMed · Cited by 114
Antineoplastic agents and the liver
Ménard, D. B., Gisselbrecht, C., Marty, M. E., Reyes, F., & Dhumeaux, D. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90205-x · Cited by 108
Syndrome of Idiopathic Hyperammonemia after High-Dose Chemotherapy: Review of Nine Cases
Mitchell, R. B., Wagner, J. J., Karp, J. E., Watson, A. J., Brusilow, S. W., Przepiorka, D., Saral, R., Storb, R. F., Santos, W., & Burke, P. J. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80239-0 · Cited by 107
Tamoxifen-associated steatohepatitis - report of three cases
Cortez‐Pinto, H., Baptista, A., Camilo, M., Costa, E. B., Valente, A. I., & de Moura, M. C. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80316-5 · Cited by 97
Capizzi, R. L., Bertino, J. R., & Handschumacher, R. E. (1970) · Annual Review of Medicine · doi:10.1146/annurev.me.21.020170.002245 · Cited by 96
Hepatic Veno-occlusive Disease Associated with Renal Transplantation and Azathioprine Therapy
Read, A. E., WIESNER, R. H., LaBRECQUE, D. R., TIFFT, J. G., MULLEN, K. D., SHEER, R. L., PETRELLI, M., RICANATI, E. S., & McCULLOUGH, A. J. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-5-651 · Cited by 92
Antecedent liver disease and drug toxicity
Schenker, S., Martin, R. R., & Hoyumpa, A. M. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80325-0 · Cited by 90
Tolman, K. G., Clegg, D. O., Lee, R. G., & Ward, J. R. (1985) · PubMed · Cited by 87
Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide
Teicher, B. A., Crawford, J. M., Holden, S. A., Lin, Y. J., Cathcart, K. N. S., Luchette, C. A., & Flatow, J. (1988) · Cancer · doi:10.1002/1097-0142(19881001)62:7<1275::aid-cncr2820620705>3.0.co;2-i · Cited by 84
MORPHOLOGIC SPECTRUM OF DRUG-INDUCED HEPATIC DISEASE
Ishak, K. G., & Zimmerman, H. J. (1995) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00227-2 · Cited by 81
Hepatotoxicity of Mercaptopurine
Shorey, J. W. (1968) · Archives of Internal Medicine · doi:10.1001/archinte.1968.00300060056011 · Cited by 81
Methotrexate hepatotoxicity in children with leukemia
McIntosh, S., Davidson, D. L., O’Brien, R. T., & Pearson, H. A. (1977) · The Journal of Pediatrics · doi:10.1016/s0022-3476(77)80587-8 · Cited by 74
Woods, W. G., Dehner, L. P., Nesbit, M. E., Krivit, W., Coccia, P. F., Ramsay, N. K. C., Kim, T. H., & Kersey, J. H. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90368-x · Cited by 72
Fisher, B., Keenan, A. M., Garra, B. S., Steinberg, S. M., White, D. E., DIBISCEGLIE, A., Hoofnagle, J. H., Yolles, P., Rosenberg, S. A., & Lotze, M. T. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1852 · Cited by 70
Cyclophosphamide-Associated Hepatotoxicity
Goldberg, J. W., & Lidsky, M. D. (1985) · Southern Medical Journal · doi:10.1097/00007611-198502000-00034 · Cited by 64
Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn?
Riordan, S. M., & Williams, R. L. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80326-2 · Cited by 63
Topoisomerase I Inhibitors: An Overview of the Camptothecin Analogs
Burris, H. A., & Jones, S. F. (1994) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30176-x · Cited by 59
Chemotherapeutic agents and hepatotoxicity.
Perry, M. C. (1992) · PubMed · Cited by 57
Self-citationCyclophosphamide Hepatotoxicity in a Patient with Systemic Lupus Erythematosus
Bacon, A. M., & ROSENBERG, S. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-62 · Cited by 56
Hepatoma in a Child With Methotrexate-Induced Hepatic Fibrosis
Ruymann, F. B. (1977) · JAMA · doi:10.1001/jama.1977.03280250057025 · Cited by 53
6-Thioguanine as a cause of toxic veno-occlusive disease of the liver
Satti, M., Weinbren, K., & Gordon‐Smith, E. C. (1982) · Journal of Clinical Pathology · doi:10.1136/jcp.35.10.1086 · Cited by 47
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth
Lahiri, S. R., Boileau, G., & Hall, T. C. (1971) · Cancer · doi:10.1002/1097-0142(1971)28:4<907::aid-cncr2820280414>3.0.co;2-9 · Cited by 46
Intestinal and liver toxicity of antineoplastic drugs.
McDonald, G. B., & Tirumali, N. (1984) · PubMed Central · Cited by 45
Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments
Tran, A., Housset, C., Boboc, B., Tourani, J. M., Carnot, F., & Berthelot, P. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90905-q · Cited by 45
Hepatotoxicity in the treatment of acute lymphoblastic leukaemia
Topley, J. M., Benson, J., Squier, M. V., & Chessells, J. M. (1979) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950070415 · Cited by 44
Hepatic injury during doxorubicin therapy.
Avilés, A., Herrera, J., Ramos, E., Ambríz, R., Aguirre, J. P. V., & Pizzuto, J. (1984) · PubMed · Cited by 43
Hepatic vascular lesions associated with dacarbazine treatment.
Greenstone, M. A., Dowd, P. M., Mikhailidis, D. P., & Scheuer, P. J. (1981) · BMJ · doi:10.1136/bmj.282.6278.1744 · Cited by 34
Cyclophosphamide-induced Liver Necrosis: A Possible Interaction with Azathioprine
Shaunak, S., Munro, J. M., Weinbren, K., et al. (1988) · QJM · doi:10.1093/oxfordjournals.qjmed.a068201 · Cited by 33
Hohenhaus, A. E., & Matus, R. E. (1990) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.1990.tb03115.x · Cited by 30
Cardiovascular risk factors in middle-aged men in 24 towns
Fowlie, D. G. (1981) · BMJ · doi:10.1136/bmj.283.6298.1058 · Cited by 29
Drug elimination in chronic liver diseases
Huet, P., Villeneuve, J., & Fenyves, D. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80498-9 · Cited by 27
Hepatic Toxicity of Drugs Used for Hematologic Neoplasia
Sznol, M., Ohnuma, T., & Holland, J. (1987) · Seminars in Liver Disease · doi:10.1055/s-2008-1040580 · Cited by 24
HEPATOTOXICITY OF ACTINOMYCIN-D
Pritchard, J., Raine, J., & Wallendszus, K. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91192-6 · Cited by 24
Cholestatic hepatitis following flutamide
Rosman, A. S., Frissora-Rodeo, C., Marshall, A. T., Reiter, B. P., & Paronetto, F. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303188 · Cited by 23
Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer
Foitl, D. R., Hyman, G. A., & Lefkowitch, J. H. (1989) · Cancer · doi:10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o · Cited by 23
Remick, S. C., Benson, A. B., Weese, J. L., Willson, J. K. V., Ramírez, G., Wirtanen, G. W., Alberti, D. B., Nieting, L. M., Tutsch, K. D., & Fischer, P. H. (1989) · PubMed · Cited by 18
FATAL LIVER CIRRHOSIS ASSOCIATED WITH LONG-TERM ARTERIAL INFUSION OF FLOXURIDINE
Pettavel, J., Gardiol, D., Bergier, N., & Schnyder, P. A. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90574-x · Cited by 17
Cited by
Karoui, M., Penna, C., Amin-Hashem, M., Mitry, E., Benoist, S., Franc, B., Rougier, P., & Nordlinger, B. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000193603.26265.c3 · Cited by 721
Tsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Sp1 transcription factor: A long-standing target in cancer chemotherapy
Vizcaíno, C., Mansilla, S., & Portugal, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.008 · Cited by 377
Clinical Biochemistry of Hepatotoxicity
P Sharma, O. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s4-001 · Cited by 305
Metadata
- Authors
- King, P. D., & Perry, M. C.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 6
- Issue
- 2
- Pages
- 162-176
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2140279988
- Cited by
- 454
- References
- 82
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.